BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 404 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 404 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $10,916.08. Following the transaction, the executive vice president now directly owns 262,715 shares of the company's stock, valued at $7,098,559.30. This trade represents a 0.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

BioLife Solutions Stock Up 2.1 %

Shares of BLFS stock traded up $0.58 during trading hours on Wednesday, hitting $27.69. 270,111 shares of the company were exchanged, compared to its average volume of 217,162. BioLife Solutions, Inc. has a 52 week low of $14.50 and a 52 week high of $28.88. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The business has a 50 day moving average of $25.91 and a two-hundred day moving average of $24.27. The company has a market capitalization of $1.28 billion, a PE ratio of -26.12 and a beta of 1.92.

Analysts Set New Price Targets

BLFS has been the subject of several analyst reports. Benchmark reissued a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. TD Cowen increased their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. KeyCorp raised their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. Northland Securities boosted their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research report on Wednesday. Finally, Craig Hallum raised their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.43.

Hedge Funds Weigh In On BioLife Solutions

Institutional investors have recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its position in shares of BioLife Solutions by 4.7% in the third quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider's stock valued at $4,776,000 after purchasing an additional 8,580 shares during the last quarter. Barclays PLC boosted its position in shares of BioLife Solutions by 20.1% during the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider's stock worth $1,613,000 after acquiring an additional 10,803 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider's stock worth $21,107,000 after buying an additional 18,473 shares in the last quarter. State Street Corp lifted its stake in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock valued at $35,364,000 after purchasing an additional 95,788 shares during the last quarter. Finally, Stifel Financial Corp grew its holdings in shares of BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock worth $325,000 after purchasing an additional 670 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.